Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study adds evidence suggesting a genetic component to frontal fibrosing alopecia, with daughters experiencing an earlier onset than their mothers, although the clinical pattern remains similar to non-familial cases.

This article discusses the pseudo 'fringe sign' in frontal fibrosing alopecia, highlighting that it is not solely related to traction, and it reports no new clinical results.

This study found that FGF5-/- rabbits exhibited a significant long hair phenotype by prolonging the anagen phase, suggesting FGF5 acts as a negative regulator of hair growth.

This review hypothesizes that excessive facial photo-protection may contribute to frontal fibrosing alopecia by disrupting immunological homeostasis through the aryl hydrocarbon receptor-kynurenine pathway, but it reports no new clinical results.

In this study, FAPD was characterized in a Chinese population by perifollicular mast cell infiltration, suggesting young individuals may be at higher risk than previously thought.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.

This review discusses the applications and research on fibroblast growth factors, including their use in wound healing, diabetes, and cancer, but it reports no new clinical results.

This study reviewed the pharmacological properties of fesoterodine and found that its ability to effectively treat overactive bladder, especially in the elderly, is likely due to its specific properties, including its receptor affinity, blood-brain barrier penetration, metabolic conversion, and extended-release formulation.

Among patients with biopsy-proven FAPD in specialized hair clinics, this study found the condition is common in females around 52.5 years old, with treatment generally stabilizing or slightly improving hair loss, despite challenges in differentiating FAPD from androgenetic alopecia.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

The document concludes that using gadolinium-based contrast agents during MRI can be linked to Nephrogenic Systemic Fibrosis in patients with severe kidney disease.

This review highlights PRF's potential as a regenerative medicine tool, detailing its diverse applications in dentistry, orthopedics, and dermatology, but presents no new clinical results.

This review discusses the diverse roles of Frizzled proteins in developmental and homeostatic processes and reports no new experimental findings.

This study found that fibroblasts from Emery-Dreifuss muscular dystrophy patients with certain genetic mutations overexpress markers of fibrosis, and gene correction techniques reduced fibrogenic molecule expression in cell models, suggesting potential therapeutic applications.

This study developed a novel ferritin-based delivery system (LR@Fn) that effectively co-delivers RG108 and LLY283 for hearing loss treatment in animal models, reducing hair cell loss and synaptic damage more effectively than dexamethasone.

This study developed a kidney-specific knockout mouse model lacking the Flcn gene, which recapitulates human Birt-Hogg-Dubé kidney tumorigenesis and shows that mTOR pathway inhibition with rapamycin can suppress tumor growth.

This review discusses the enigmatic nature of frontal fibrosing alopecia and reports no clinical results; the authors stress the need for further research.

This review discusses frontal fibrosing alopecia in males and reports no new clinical results, indicating a broader demographic affected by this inflammatory disorder beyond postmenopausal women.

The document recommends a multidisciplinary approach and experience sharing to advance facial feminization surgery as a medical field.

This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.

This study found that frontal fibrosing alopecia involves distinct molecular changes, such as downregulation of steroid and cholesterol pathways and upregulation of fibrotic and immune response genes, which may help guide treatment strategies.

In this case series, researchers reported on the clinical characteristics and treatment approaches for Frontal Fibrosing Alopecia in four cases, emphasizing the importance of early identification and intervention to manage this scarring hair loss disorder that primarily affects the frontal hairline and eyebrows.

This review discusses frontal fibrosing alopecia and reports no clinical results; the authors note that no therapeutic options tested, including corticosteroids, finasteride, and minoxidil, have shown clear benefits.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This case report describes the first known instance of fixed drug eruption linked to finasteride, confirmed through an oral challenge test that reproduced symptoms at the same skin site.

This study found that facial papules and rosacea in patients with frontal fibrosing alopecia were linked to a greater need for oral treatment, with most cases involving postmenopausal women.

This case report describes a family with autosomal dominant transmission of keratosis follicularis spinulosa decalvans, with observed treatment refractoriness in multiple topical and systemic therapies.

Fibrosing alopecia in a pattern distribution is a unique hair loss condition with inflammation and scarring, resembling but distinct from common balding.

Finasteride may help treat frontal fibrosing alopecia, but more research is needed.

This report suggests that patients with primary spontaneous pneumothorax should be evaluated for FLCN mutations, as they may indicate Birt-Hogg-Dube syndrome and associated cancer risks.